Free Trial

Accelerate Diagnostics Q3 2023 Earnings Report

Accelerate Diagnostics logo
$1.32 +0.01 (+0.76%)
As of 01/30/2025 03:50 PM Eastern

Accelerate Diagnostics EPS Results

Actual EPS
-$0.92
Consensus EPS
-$0.94
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Accelerate Diagnostics Revenue Results

Actual Revenue
$3.30 million
Expected Revenue
$3.60 million
Beat/Miss
Missed by -$300.00 thousand
YoY Revenue Growth
N/A

Accelerate Diagnostics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Accelerate Diagnostics Earnings Headlines

StockNews.com Begins Coverage on Accelerate Diagnostics (NASDAQ:AXDX)
We recommended Palantir in 2021, now we're recommending this...
Simply put: All the grandiose claims you hear about AI will amount to nothing without one key investment. That's why I believe the biggest AI gains will NOT come from the "Next NVIDIA"... or some obscure AI startup you've never heard of. In fact, I'm convinced the biggest gains will come from one company that - at first glance - has nothing to do with AI at all. It's a Texas-based firm that provides the backbone for the entire $15.7 trillion AI industry.
See More Accelerate Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Accelerate Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Accelerate Diagnostics and other key companies, straight to your email.

About Accelerate Diagnostics

Accelerate Diagnostics (NASDAQ:AXDX), an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

View Accelerate Diagnostics Profile

More Earnings Resources from MarketBeat